JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX

Key Points

• JPMorgan Chase reduced its stake in Perspective Therapeutics by 41.7% in Q3, selling 311,710 shares and leaving 436,357 shares (~0.59% ownership) valued at about $1.497 million.
• A number of other institutions increased or initiated positions (Vanguard, Bank of America, UBS, Geode, Patient Square), leaving institutional ownership at 54.66%.
• Analysts are largely bullish (one Strong Buy, eight Buy) with an average price target of $12.63, versus the stock trading around $4.37; the company reported recent quarterly EPS of -$0.51 on just $0.04M revenue and expected -$0.88 EPS for the year.

JPMorgan Chase & Co. lessened its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) by 41.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 436,357 shares of the company's stock after selling 311,710 shares during the period. JPMorgan Chase & Co. owned approximately 0.59% of Perspective Therapeutics worth $1,497,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company's stock valued at $11,792,000 after buying an additional 163,532 shares in the last quarter. Geode Capital Management LLC increased its position in Perspective Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company's stock valued at $4,758,000 after buying an additional 188,887 shares in the last quarter. Bank of America Corp DE increased its position in Perspective Therapeutics by 139.9% during the 3rd quarter. Bank of America Corp DE now owns 785,823 shares of the company's stock valued at $2,695,000 after buying an additional 458,323 shares in the last quarter. UBS Group AG increased its position in Perspective Therapeutics by 72.0% during the 3rd quarter. UBS Group AG now owns 641,143 shares of the company's stock valued at $2,199,000 after buying an additional 268,433 shares in the last quarter. Finally, Patient Square Capital LP purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at $1,198,000. Institutional investors own 54.66% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the company. BTIG Research reiterated a "buy" rating and set a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. UBS Group increased their target price on Perspective Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, March 18th. B. Riley Financial increased their target price on Perspective Therapeutics from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, March 18th. Wedbush reiterated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 18th. Finally, Royal Bank Of Canada cut their target price on Perspective Therapeutics from $18.00 to $14.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.63.

Perspective Therapeutics Price Performance

CATX stock opened at $4.37 on Thursday. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.17 and a current ratio of 5.17. The stock's fifty day moving average price is $4.83 and its 200-day moving average price is $3.53.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. The firm had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%. Equities analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.